FDA's Irresponsible Actions Endanger Children, Ted Cruz Warns
Submitted by MAGA
Posted 111 days ago
**Alarming FDA Decisions Place Children at Risk, Says Ted Cruz**
In a shocking revelation, Senator Ted Cruz has sharply criticized the U.S. Food and Drug Administration (FDA) for prioritizing radical gender ideology over the safety of vulnerable children.
Cruz's remarks come in the wake of internal emails that surfaced, revealing the agency's consideration of puberty blockers for "transgender" minors, despite acknowledging the associated severe risks, including heightened suicidal ideation and depression.
"This is beyond troubling," Cruz stated. "The Biden-Harris administration’s agenda appears to place the promotion of radical gender ideology ahead of our children's well-being."
The emails, obtained by America First Legal during a legal scrutiny of the FDA's practices, expose a significant disconnect between the agency’s purported commitment to child safety and its actions regarding experimental medical interventions for minors experiencing gender dysphoria.
In a communication dated January 25, 2022, FDA team leader Shannon Sullivan confirmed that the agency had conducted a safety review of GnRH agonists, which are used to block natural puberty. Notably, this review cited risks for suicidal thoughts and other serious health issues.
Despite these alarming findings, Sullivan recommended approval for the use of GnRH agonists in gender transition cases, suggesting a troubling prioritization of ideology over empirical data on health risks.
The FDA’s complicity in advancing these treatments raises critical questions about accountability and ethical governance in the realm of childhood health care. Cruz argues that such reckless policies not only endanger children but also reflect a broader trend within the government that dismisses the ramifications of gender transition treatments.
Ian Prior, a senior adviser at America First Legal, echoed similar concerns, stating, “The advocates of these brutal practices on children claim that they are necessary to prevent suicide and depression, but in reality, the treatments themselves cause the very issue they claim to combat.”
As investigations into the FDA's conduct continue, Cruz and other concerned lawmakers are calling on the federal government to adopt policies that align with the safety and well-being of children, urging a reevaluation of practices that could have permanent consequences on young lives.
In a time when parental rights and child safety should take precedence, the FDA’s actions appear decidedly misaligned with national values. Cruz's critique emphasizes the urgent need for reform to protect our youth from potentially devastating medical interventions driven by ideological motives.
This alarming revelation not only calls for increased scrutiny of the FDA but also reinforces the importance of protecting children from experimental treatments. As debates about gender identity and medical intervention swirl, the safety of children must always remain the foremost concern.
Sources:
dailysignal.com
100percentfedup.com
wentworthreport.com
In a shocking revelation, Senator Ted Cruz has sharply criticized the U.S. Food and Drug Administration (FDA) for prioritizing radical gender ideology over the safety of vulnerable children.
Cruz's remarks come in the wake of internal emails that surfaced, revealing the agency's consideration of puberty blockers for "transgender" minors, despite acknowledging the associated severe risks, including heightened suicidal ideation and depression.
"This is beyond troubling," Cruz stated. "The Biden-Harris administration’s agenda appears to place the promotion of radical gender ideology ahead of our children's well-being."
The emails, obtained by America First Legal during a legal scrutiny of the FDA's practices, expose a significant disconnect between the agency’s purported commitment to child safety and its actions regarding experimental medical interventions for minors experiencing gender dysphoria.
In a communication dated January 25, 2022, FDA team leader Shannon Sullivan confirmed that the agency had conducted a safety review of GnRH agonists, which are used to block natural puberty. Notably, this review cited risks for suicidal thoughts and other serious health issues.
Despite these alarming findings, Sullivan recommended approval for the use of GnRH agonists in gender transition cases, suggesting a troubling prioritization of ideology over empirical data on health risks.
The FDA’s complicity in advancing these treatments raises critical questions about accountability and ethical governance in the realm of childhood health care. Cruz argues that such reckless policies not only endanger children but also reflect a broader trend within the government that dismisses the ramifications of gender transition treatments.
Ian Prior, a senior adviser at America First Legal, echoed similar concerns, stating, “The advocates of these brutal practices on children claim that they are necessary to prevent suicide and depression, but in reality, the treatments themselves cause the very issue they claim to combat.”
As investigations into the FDA's conduct continue, Cruz and other concerned lawmakers are calling on the federal government to adopt policies that align with the safety and well-being of children, urging a reevaluation of practices that could have permanent consequences on young lives.
In a time when parental rights and child safety should take precedence, the FDA’s actions appear decidedly misaligned with national values. Cruz's critique emphasizes the urgent need for reform to protect our youth from potentially devastating medical interventions driven by ideological motives.
This alarming revelation not only calls for increased scrutiny of the FDA but also reinforces the importance of protecting children from experimental treatments. As debates about gender identity and medical intervention swirl, the safety of children must always remain the foremost concern.
Sources:
dailysignal.com
100percentfedup.com
wentworthreport.com
Latest News